Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Income from Continuing Operations of 3855000.0 for Q1 2026, down 57.49% year-over-year from 9069000.0 in Q1 2025, and up 106.23% quarter-over-quarter from 61915000.0 in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Income from Continuing Operations for 10 consecutive years, with 3855000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 57.49% year-over-year to 3855000.0; the TTM figure through Mar 2026 stood at 53495000.0 (down 15.43% YoY), while the FY2025 annual figure was 66042000.0, down 6.86% from the prior year.
- Income from Continuing Operations advanced to 3855000.0 in Q1 2026 per SLGL's latest filing, from 61915000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11063000.0 in Q1 2023 and bottomed at 61915000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 11548647.06 across 5 years, with a median of 828000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 1509.72% — and 2025, when it soared 731.65%.
- Sol-Gel Technologies' Income from Continuing Operations stood at 50899000.0 in 2022, then retreated by 4.75% to 53319000.0 in 2023, then declined by 4.82% to 55889000.0 in 2024, then fell by 10.78% to 61915000.0 in 2025, then jumped by 106.23% to 3855000.0 in 2026.
- Business Quant data shows SLGL's Income from Continuing Operations at 3855000.0 in Q1 2026, 61915000.0 in Q4 2025, and 6288000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -4.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.64 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 10.85 Mn |
| Mar 31, 2025 | 9.07 Mn |
| Dec 31, 2024 | -6.10 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | -5.41 Mn |
| Sep 30, 2023 | -6.31 Mn |
| Jun 30, 2023 | -7.08 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 13.96 Mn |
| Sep 30, 2021 | 1.27 Mn |